Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients
Congenital Heart Diseases, Aortic Valve Disorder
About this trial
This is an interventional prevention trial for Congenital Heart Diseases
Eligibility Criteria
Inclusion Criteria:
- Patient less than or equal to 1 year of age who is undergoing cardiovascular surgery requiring CPB or patient under 18 years of age undergoing procedures involving aortic valve or aorta
- Patients with a positive MRSA screen or a history of MRSA infections who are undergoing any cardiac surgery
Exclusion Criteria:
- Patients who have known hypersensitivity to vancomycin or cephalosporins
- Patients with renal insufficiency
- Patients who have received vancomycin or cephalosporins 48 hours prior to the day of surgery
- Patients whose surgery is due to an infection-related diagnosis such as endocarditis
- Patients whose parents do not wish to have them receive vancomycin prophylaxis
- Neonates born at less than 38 weeks gestational age
Sites / Locations
- Lucile Packard Children's Hospital at Stanford
Arms of the Study
Arm 1
Arm 2
Active Comparator
Other
Cefazolin 25 mg/kg body weight and vancomycin
Cefazolin only 30mg/kg body weight
All infants < 1 year of age with congenital heart diseases requiring cardiac surgery with cardiopulmonary bypass or any patient who requires surgery involving the aorta or the aortic valve will receive both Cefazolin and Vancomycin as preoperative prophylaxis against Surgical Site Infections. This has been recommended in recently published guidelines but not evaluated in children. Intervention: Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride 15 mg/kg body weight
All infants less than one year of age with congenital heart diseases requiring cardiac surgery with cardiopulmonary bypass or all patients who required surgery involving the aorta or the aortic valve received cefazolin 30 mg/kg body weight as preoperative prophylaxis against surgical site infections